Gene · 140
Papers1,628
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 1,628
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exploring Non-orthosteric Interactions with a Series of Potent and Selective A3 Antagonists. | ACS Med Chem Lett | 2022 | 35178181 | PubTator, text mining | PubMed |
| Single Stabilizing Point Mutation Enables High-Resolution Co-Crystal Structures of the Adenosine A2A Receptor with Preladenant Conjugates. | Angew Chem Int Ed Engl | 2022 | 35174942 | PubTator, text mining | PubMed |
| Non-Invasive Assessment of Locally Overexpressed Human Adenosine 2A Receptors in the Heart of Transgenic Mice. | Int J Mol Sci | 2022 | 35162950 | PubTator, text mining | PubMed |
| Recovery of Dysregulated Genes in Cancer-Related Lower Limb Lymphedema After Supermicrosurgical Lymphaticovenous Anastomosis - A Prospective Longitudinal Cohort Study. | J Inflamm Res | 2022 | 35153500 | PubTator, text mining | PubMed |
| Pharmacological Study of A3 Adenosine Receptor agonist (AB Meca) in Xenograft Lung Cancer Model in Mice through In Silico and In Vivo Approach: Targeting TNF-α. | Curr Drug Discov Technol | 2022 | 35135461 | PubTator, text mining | PubMed |
| Intraocular implants loaded with A3R agonist rescue retinal ganglion cells from ischemic damage. | J Control Release | 2022 | 35131370 | PubTator, text mining | PubMed |
| Targeting the A3 adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice. | Acta Neuropathol Commun | 2022 | 35093182 | PubTator, text mining | PubMed |
| Purinergic signaling elements are correlated with coagulation players in peripheral blood and leukocyte samples from COVID-19 patients. | J Mol Med (Berl) | 2022 | 35091759 | PubTator, text mining | PubMed |
| Structure-activity features of purines and their receptors: implications in cell physiopathology. | Mol Biomed | 2022 | 35079944 | PubTator, text mining | PubMed |
Comparison of chemical profiles, antioxidation, inhibition of skin extracellular matrix degradation, and anti-tyrosinase activity between mycelium and fruiting body of Cordyceps militaris and Isaria tenuipes. | Pharm Biol | 2022 | 35068295 | PubTator, text mining | PubMed |
| Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A1 Antagonists. | J Med Chem | 2022 | 35068155 | PubTator, text mining | PubMed |
| Identification of Druggable Genes for Asthma by Integrated Genomic Network Analysis. | Biomedicines | 2022 | 35052792 | PubTator, text mining | PubMed |
| 2‑Cl‑IB‑MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines. | Int J Mol Med | 2022 | 35039871 | PubTator, text mining | PubMed |
| Taxifolin improves inflammatory injury of human bronchial epithelial cells by inhibiting matrix metalloproteinase (MMP) 10 via Wnt/β-catenin pathway. | Bioengineered | 2022 | 35000533 | PubTator, text mining | PubMed |
| Purinergic modulation of the immune response to infections. | Purinergic Signal | 2022 | 34997903 | PubTator, text mining | PubMed |
| Effect of long-chain inorganic polyphosphate treated with wheat phytase on interleukin 8 signaling in HT-29 cells. | Anim Biosci | 2022 | 34991200 | PubTator, text mining | PubMed |
| A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity. | Eur J Med Chem | 2022 | 34844790 | PubTator, text mining | PubMed |
| Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. | Stroke | 2022 | 34802248 | PubTator, text mining | PubMed |
| A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling. | Purinergic Signal | 2022 | 34757513 | PubTator, text mining | PubMed |
| Cancer biology and molecular genetics of A3 adenosine receptor. | Oncogene | 2022 | 34750517 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/140/papers?page=19